ABSTRACT
INTRODUCTION
Percutaneous coronary intervention (PCI), usually with stenting, has become the standard treatment for Acute coronary syndromes (ACS). During this procedure, trauma commonly occurs to the arterial endothelium that, among other effects, causes the activation and aggregation of platelets. Because platelet aggregation may lead to coronary thrombosis in a patient already vulnerable to it, Antiplatelet agents are essential adjunctive therapies in patients with ACS undergoing PCI. The goal of Antiplatelet therapy is to provide maximal protection against thrombosis without increasing the risk of bleeding. 1 ST-segment elevation myocardial infarction (STEMI) accounts for approximately 30-45% of an estimated 1.5 million hospitalizations for acute coronary syndromes annually. 2 Treatment includes drugs like aspirin, clopidogrel and ticagrelor. Thrombolysis in Myocardial Infarction (TIMI) grading system and Myocardial perfusion grade (MPG) are angiographic markers of efficacy of coronary reperfusion at the epicardial artery and microcirculation levels. 3 The completeness of restoration of the epicardial blood flow after recanalization of infarct-related artery has been quantified with the Thrombolysis in Myocardial Infarction (TIMI) grading system. 4 In most cases clopidogrel is used rather than ticagrelor so we concluded that clopidogrel is safest thanticagrelor.
Aim
To assess the improvement of therapeutic outcomes between clopidogrel and ticagrelor in patients undergoing primary Percutaneous coronary intervention (PCI) in AMI Patients
Objectives
• To evaluate Myocardial perfusion (TIMI grade flow) Score after PPCI.
• Assessment of RWMA (Regional Wall Motion Abnormality).
• To evaluate LV size Left ventricular ejection fraction % (LVEF) after PPCI.
• To assess the ECG changes after PPCI.
• To assess incidence of serious bleeding events and major adverse cardiovascular events after PPCI. 
METHODOLOGY

RESULTS AND DISCUSSION
A total no of 60 patients 53 males (88.33%) and 7 female (11.62%) who have been admitted with AMI in intensive cardiac care unit, were monitored for efficacy and safety of pretreated anti-platelet therapy. The range of study population was 19-80 years (mean age ± S.D was 65.27 ± 9.333 years) BMI range was found to be 20 to 27 kg/m 2 (mean BMI ± S.D 23.75 ± 1.609 kg/m 2 ) the reperfusion therapy was performed <12 h of onset of symptoms. Table 1 shows that award of the score for different parameters in response to antiplatelet therapy with PCI. Table 2 shows that the distribution of 30 patients in both clopidogrel and ticagrelor group.
The anti-platelet therapy given to the patients was described in Table 2 of 60 patients, 30 (50%) patients were prescribed with Clopidogrel, 30 (50%) Patients were prescribed with Ticagrelor. Table 3 Shows the Clopidogrel treated patients are total 30 patients, among them 26 of male patients (86.66 %) there are very less number of female patients 4 (13.3%). The Ticagrelor treated patients are a total 30 patients among them 27 of male patients (90.00%) and there are very less number of female patients 3(10%). There are no patients of either gender in the age of 19 -30 years in both Clopidogrel and Ticagrelor patients. There are 50% of male patients with the range of age between 61-70 years in each group. 
Mortality after PPCI:
In our study period we did not noticed mortality after PPCI.
From Table 8 (5) they observed the potential benefit of pretreatment with Clopidogrel particularly TIMI -3 flow grade. Therefore pretreatment with a higher Clopidogrel dose may also improve TIMI flow at the end of procedure. The pumping capacity of the heart LVEF more than 50% was observed in Clopidogrel pretreated patients 8 (26.66) with the mean score of 1.0 and > 50% was observed in Ticagrelor pretreated patients 16 (53.33%) with the mean score of 1.46. Yumei Ye, Gilad D. Birnbaum et al., 6 were observed that improved heart function in Ticagrelor pretreated patients. Therefore our study supports Ticagrelor shows improved heart function as compared with clopidogrel pretreated candidates undergoing PPCI. The mean score of ECG changes in clopidogrel were 0.50 and in Ticagrelor pretreated patients are 0.66. There four there is no significant difference was observed in ST Segment resolution in Clopidogrel and Ticagrelor pretreated patients. Lars Wallentin, Richard et al., 7, 8 observed Ticagrelor shows that better ST Segment resolution. The Regional Wall Motion Abnormalities (RWMA) are observed that in Clopidogrel pretreated patients 9 (30.00%) are with Hypokinetic with the mean score of 1.86 and in Ticagrelor pretreated patients 14 (46.66%) with the mean score of 2.10 respectively. Therefore Ticagrelor shows more efficacious than Clopidogrel in all aspects, except ECG (ST segment resolution) changes.
CONCLUSION
The finding in our study concludes that the Ticagrelor was more efficacious than clopidogrel in the clinical end poins of Myocardial grade flow, Regional wall motion abnormalities, left ventricular ejection fraction, left ventricular size and ST segment resolution. We are not observed any adverse drug reaction with both Ticagrelor and clopidogrel pretreated groups.
LIMITATIONS OF THE STUDY
In our study there are inadequate number of populations/ less sample size in group of patients. We did not conduct follow up after reperfusion therapy in PPCI patents, there four we are not noticed mortality and adverse drug reactions with anti-platelet drugs.
